RZLTNasdaqPharmaceutical PreparationsFiscal year ends June 30
Rezolute, Inc.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 24, 2026
$3.70+0.12 (+3.35%)
Close on Oct 19, 2026
- Market cap
- $386.60M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
89.6%
87M of 97M shares
Institutional holders
144
39 new, 19 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
10 buys · 0 sales
Net bought $289.05K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Ann C. Donahue | 8,250,274 | 19.99% | 13G (passive) amendment | Dec 31, 2023 |
| Opaleye Management Inc. | 6,300,000 | 6.58% | 13G (passive) amendment | Mar 31, 2026 |
| Kevin Pyun | 5,721,834 | 5.90% | 13G (passive) | Aug 5, 2026 |
| Balyasny Asset Management Holdings LP | 5,048,421 | 5.28% | 13G (passive) | Mar 31, 2026 |
| Wilmot B. Harkey | 4,966,717 | 8.60% | 13G (passive) amendment | Sep 30, 2024 |
| BlackRock, Inc. | 4,881,509 | 5.40% | 13G (passive) | Sep 30, 2025 |
| Raymond Debbane | 4,870,000 | 5.40% | 13G (passive) | Sep 18, 2025 |
| RA Capital Healthcare Fund, L.P. | 15,302,186 | 9.90% | 13G (passive) | Dec 11, 2025 |
| Abigail P. Johnson | 12,811,876 | 15.00% | 13G (passive) amendment | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RZLT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Federated Hermes, Inc. | 12,990,659 | 13.43% | $67.55M | – | 0.10% |
| Ra Capital Management, L.P. | 9,445,039 | 9.77% | $49.11M | +265,039 | 0.43% |
| BlackRock, Inc. | 7,718,291 | 7.98% | $40.14M | +1,404,788 | 0.00% |
| Opaleye Management Inc. | 6,300,000 | 6.51% | $32.76M | – | 2.97% |
| Balyasny Asset Management L.P. | 4,662,039 | 4.82% | $24.24M | −386,382 | 0.03% |
| Vanguard Capital Management LLC | 3,835,827 | 3.97% | $19.95M | +313,747 | 0.00% |
| Siren, L.L.C. | 3,328,287 | 3.44% | $17.31M | – | 0.35% |
| Jacobs Levy Equity Management, Inc | 2,561,654 | 2.65% | $13.32M | +2,341,247 | 0.05% |
| Jennison Associates LLC | 2,459,308 | 2.54% | $12.79M | −979,573 | 0.01% |
| Geode Capital Management, LLC | 2,170,154 | 2.24% | $11.29M | +205,795 | 0.00% |
| State Street Corp | 1,850,128 | 1.91% | $9.62M | +78,287 | 0.00% |
| D. E. Shaw & Co., Inc. | 1,839,357 | 1.90% | $9.56M | +73,377 | 0.00% |
| Morgan Stanley | 1,618,783 | 1.67% | $8.42M | −1,128,888 | 0.00% |
| Vanguard Portfolio Management LLC | 1,380,746 | 1.43% | $7.18M | −1,601,019 | 0.00% |
| Goldman Sachs Group Inc | 1,316,782 | 1.36% | $6.85M | +714,486 | 0.00% |
| Nuveen, LLC | 1,295,209 | 1.34% | $6.74M | +1,197,523 | 0.00% |
| Kennedy Capital Management LLC | 1,221,678 | 1.26% | $6.35M | −14,420 | 0.11% |
| Blackstone Inc. | 1,082,927 | 1.12% | $5.63M | New | 0.02% |
| Aqr Capital Management LLC | 1,007,962 | 1.04% | $5.24M | +211,266 | 0.00% |
| Affinity Asset Advisors, LLC | 1,000,000 | 1.03% | $5.20M | −547,641 | 0.24% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 144 | 87M | 89.6% | 39 / 60 | 29 / 19 | 13M | 13M |
| Q1 2026 | 125 | 86M | 89.2% | 34 / 37 | 39 / 30 | 22M | 21M |
| Q4 2025 | 122 | 90M | 93.5% | 41 / 44 | 25 / 34 | 42M | 38M |
| Q3 2025 | 116 | 87M | 89.9% | 35 / 39 | 29 / 11 | 18M | 9M |
| Q2 2025 | 92 | 78M | 80.6% | 43 / 33 | 13 / 28 | 39M | 6M |
| Q1 2025 | 77 | 45M | 46.6% | 18 / 31 | 18 / 12 | 11M | 9M |
| Q4 2024 | 71 | 43M | 44.7% | 22 / 23 | 19 / 9 | 9M | 3M |
| Q3 2024 | 59 | 39M | 40.2% | 19 / 20 | 10 / 11 | 4M | 7M |
| Q2 2024 | 52 | 43M | 44.0% | 24 / 18 | 6 / 5 | 16M | 1M |
| Q1 2024 | 33 | 27M | 28.0% | 8 / 9 | 6 / 7 | 3M | 6M |
| Q4 2023 | 32 | 30M | 31.5% | 4 / 11 | 5 / 2 | 9M | 2M |
| Q3 2023 | 30 | 24M | 24.7% | 2 / 4 | 10 / 1 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of RZLT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Federated Hermes Kaufmann Fund | 7,484,000 | 7.74% | $35.32M | 0.72% | Jul 31, 2026 |
| Federated Hermes Kaufmann Small Cap Fund | 5,340,860 | 5.52% | $25.21M | 0.89% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 2,744,647 | 2.84% | $14.27M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,065,733 | 2.14% | $10.74M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,005,732 | 1.04% | $5.23M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 856,711 | 0.89% | $4.04M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 636,980 | 0.66% | $3.31M | 0.02% | Jun 30, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 629,453 | 0.65% | $3.27M | 0.10% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 450,654 | 0.47% | $1.49M | 0.00% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 411,571 | 0.43% | $1.36M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 372,322 | 0.38% | $1.23M | 0.01% | May 31, 2026 |
| Janus Henderson Small Cap Growth Alpha ETF | 320,855 | 0.33% | $1.51M | 0.42% | Jul 31, 2026 |
| Dimensional U.S. Small Cap ETF | 319,926 | 0.33% | $1.51M | 0.01% | Jul 31, 2026 |
| iShares Micro-Cap ETF | 263,185 | 0.27% | $1.37M | 0.09% | Jun 30, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 239,040 | 0.25% | $1.24M | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Nevan C. Elam | CEO, Director | 605,497 | 0.63% | Jul 7, 2026 |
| Sunil Ratilal Karnawat | Chief Commercial Officer | 79,173 | 0.08% | Sep 3, 2026 |
| Daron Evans | CFO | 508,400 | 0.53% | Jul 7, 2026 |
| Brian Kenneth Roberts | Chief Medical Officer | 309,351 | 0.32% | Jul 7, 2026 |
| Wladimir Hogenhuis | Director | 119,675 | 0.12% | Dec 17, 2025 |
| Philippe Fauchet | Director | 55,500 | 0.06% | Nov 21, 2025 |
| Nerissa Kreher | Director | 58,576 | 0.06% | Nov 21, 2025 |
| Gil M. Labrucherie | Director | 109,072 | 0.11% | Nov 21, 2025 |
| Young-Jin Kim | Director | 8,594,336 | 8.89% | Nov 21, 2025 |
| Erik Harris | Director | 21,000 | 0.02% | Nov 21, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Sunil Ratilal Karnawat Chief Commercial Officer | Sep 2, 2026 | Tax withholding | −2,267 | $4.50 | $10.20K | 69,275 |
| Daron Evans CFO | Jul 2, 2026 | Tax withholding | −3,062 | $4.99 | $15.28K | 411,400 |
| Brian Kenneth Roberts Chief Medical Officer | Jul 2, 2026 | Tax withholding | −3,062 | $4.99 | $15.28K | 293,851 |
| Nevan C. Elam CEO, Director | Jul 2, 2026 | Tax withholding | −8,004 | $4.99 | $39.94K | 605,497 |
| Daron Evans CFO | Mar 30, 2026 | Buy | +10,000 | $2.85 | $28.50K | 414,462 |
| Nevan C. Elam CEO, Director | Mar 2, 2026 | Tax withholding | −27,618 | $2.99 | $82.58K | 613,501 |
| Brian Kenneth Roberts Chief Medical Officer | Mar 2, 2026 | Tax withholding | −11,439 | $2.99 | $34.20K | 296,913 |
| Daron Evans CFO | Mar 2, 2026 | Tax withholding | −11,438 | $2.99 | $34.20K | 404,462 |
| Brian Kenneth Roberts Chief Medical Officer | Dec 16, 2025 | Buy | +28,000 | $1.70 | $47.60K | 308,352 |
| Wladimir Hogenhuis Director | Dec 16, 2025 | Buy | +5,650 | $1.69 | $9.55K | 119,675 |
| Daron Evans CFO | Dec 15, 2025 | Buy | +2,500 | $1.79 | $4.48K | 7,000 |
| Daron Evans CFO | Dec 15, 2025 | Buy | +2,500 | $1.79 | $4.48K | 7,000 |
| Daron Evans CFO | Dec 15, 2025 | Buy | +40,000 | $1.77 | $70.80K | 415,900 |
| Sunil Ratilal Karnawat Chief Commercial Officer | Dec 15, 2025 | Buy | +12,000 | $1.62 | $19.44K | 71,442 |
| Sunil Ratilal Karnawat Chief Commercial Officer | Dec 15, 2025 | Buy | +100 | $1.60 | $160 | 71,542 |
| Nevan C. Elam CEO, Director | Dec 15, 2025 | Buy | +32,000 | $1.59 | $50.88K | 641,119 |
| Daron Evans CFO | Dec 9, 2025 | Buy | +10,549 | $5.04 | $53.17K | 131,900 |
| Young-Jin Kim Director | Nov 19, 2025 | Award | +21,000 | – | – | 170,950 |
| Nerissa Kreher Director | Nov 19, 2025 | Award | +21,000 | – | – | 58,576 |
| Wladimir Hogenhuis Director | Nov 19, 2025 | Award | +21,000 | – | – | 114,025 |
| Nevan C. Elam CEO, Director | Nov 19, 2025 | Award | +317,000 | – | – | 609,119 |
| Gil M. Labrucherie Director | Nov 19, 2025 | Award | +21,000 | – | – | 55,500 |
| Brian Kenneth Roberts Chief Medical Officer | Nov 19, 2025 | Award | +123,000 | – | – | 280,352 |
| Philippe Fauchet Director | Nov 19, 2025 | Award | +21,000 | – | – | 55,500 |
| Sunil Ratilal Karnawat Chief Commercial Officer | Nov 19, 2025 | Award | +32,000 | – | – | 59,442 |
| Daron Evans CFO | Nov 19, 2025 | Award | +107,000 | – | – | 375,900 |
| Erik Harris Director | Nov 19, 2025 | Award | +21,000 | – | – | 21,000 |
| Sunil Ratilal Karnawat Chief Commercial Officer | Aug 18, 2025 | Award | +25,000 | – | – | 27,442 |
| Brian Kenneth Roberts Chief Medical Officer | Jun 25, 2025 | Buy | +2,500 | $4.38 | $10.95K | 15,500 |
| Daron Evans CFO | Jun 24, 2025 | Buy | +5,000 | $4.05 | $20.25K | 268,900 |
| Young-Jin Kim Director | Jun 13, 2025 | Buy | +1,230,769 | $3.25 | $4.00M | 8,423,386 |
| Nerissa Kreher Director | Jun 13, 2025 | Buy | +3,076 | $3.25 | $10.00K | 37,576 |
| Wladimir Hogenhuis Director | Jun 10, 2025 | Award | +9,000 | – | – | 93,025 |
| Gil M. Labrucherie Director | Jun 10, 2025 | Award | +9,000 | – | – | 34,500 |
| Nerissa Kreher Director | Jun 10, 2025 | Award | +9,000 | – | – | 34,500 |
| Nevan C. Elam CEO, Director | Jun 10, 2025 | Award | +68,000 | – | – | 292,119 |
| Daron Evans CFO | Jun 10, 2025 | Award | +26,000 | – | – | 263,900 |
| Philippe Fauchet Director | Jun 10, 2025 | Award | +9,000 | – | – | 34,500 |
| Brian Kenneth Roberts Chief Medical Officer | Jun 10, 2025 | Award | +26,000 | – | – | 157,352 |
| Young-Jin Kim Director | Jun 10, 2025 | Award | +9,000 | – | – | 149,950 |
| Wladimir Hogenhuis Director | Mar 31, 2025 | Buy | +6,758 | $2.92 | $19.73K | 84,025 |
| Nevan C. Elam CEO, Director | Mar 27, 2025 | Buy | +12,302 | $2.85 | $35.06K | 224,119 |
| Daron Evans CFO | Mar 26, 2025 | Buy | +10,000 | $2.88 | $28.80K | 23,000 |
| Daron Evans CFO | Mar 26, 2025 | Buy | +10,000 | $2.89 | $28.90K | 237,900 |
| Wladimir Hogenhuis Director | Feb 18, 2025 | Buy | +10,000 | $4.70 | $47.00K | 77,267 |
| Wladimir Hogenhuis Director | Feb 16, 2025 | Award | +25,500 | – | – | 67,267 |
| Gil M. Labrucherie Director | Feb 16, 2025 | Award | +25,500 | – | – | 25,500 |
| Young-Jin Kim Director | Feb 16, 2025 | Award | +25,500 | – | – | 140,950 |
| Nerissa Kreher Director | Feb 16, 2025 | Award | +25,500 | – | – | 25,500 |
| Nevan C. Elam CEO, Director | Feb 16, 2025 | Award | +204,000 | – | – | 211,817 |
| Philippe Fauchet Director | Feb 16, 2025 | Award | +25,500 | – | – | 25,500 |
| Daron Evans CFO | Feb 16, 2025 | Award | +77,000 | – | – | 227,900 |
| Brian Kenneth Roberts Chief Medical Officer | Feb 16, 2025 | Award | +77,000 | – | – | 131,352 |
| Daron Evans CFO | Dec 18, 2024 | Buy | +10,000 | $4.29 | $42.90K | 150,900 |
| Daron Evans CFO | Dec 12, 2024 | Buy | +9,000 | $4.60 | $41.40K | 140,900 |
| Wladimir Hogenhuis Director | Sep 24, 2024 | Buy | +4,259 | $4.70 | $20.02K | 41,767 |
| Young-Jin Kim Director | Jun 25, 2024 | Buy | +1,250,000 | $4.00 | $5.00M | 7,192,617 |
| Wladimir Hogenhuis Director | Jun 25, 2024 | Buy | +4,815 | $4.15 | $19.98K | 37,508 |
| Daron Evans CFO | Jun 14, 2024 | Buy | +40,000 | $4.04 | $161.60K | 40,000 |
| Brian Kenneth Roberts Chief Medical Officer | Jun 14, 2024 | Buy | +300 | $3.97 | $1.19K | 1,376 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.